Citius Oncology, Inc. CTOR Ratios & Valuation
| TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -119.9%-72.5pp | -47.4%+7.0pp | -54.4%+53.1pp | -107.5%— | —— | |
| Return on assets | -44.2%-20.7pp | -23.6%+3.1pp | -26.7%+11.0pp | -37.7%-0.6pp | -37.1%-8.8pp | |
| Liquidity | ||||||
| Current ratio | 0.5×-0.3× | 0.8×+0.3× | 0.6×+0.2× | 0.3×0.0× | 0.4×0.0× | |
| Quick ratio | 0.1×-0.2× | 0.3×+0.2× | 0.1×+0.1× | 0×0.0× | 0.1×0.0× | |
| Cash ratio | 0×-0.1× | 0.2×+0.1× | 0.1×— | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $0.35-47.2% | $0.67+9.1% | $0.61+35.2% | $0.45-9.1% | $0.50-13.7% | |
| Valuation | ||||||
| Market capitalization | $60.45M-74.7% | $84.8M-50.0% | $169.53M— | —— | —— | |
| Price / book | 1.8×-5.9× | 1.5×-2.3× | 3.8×— | —— | —— | |
| Earnings yield | -67.2%-56.6pp | -27.9%-13.3pp | -14.6%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Citius Oncology, Inc.'s ratios come from?
- Every ratio is computed from Citius Oncology, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.